

**Accelerated Article Preview****Generalizing arene C–H alkylations by radical–radical cross-coupling**

---

Received: 1 November 2024

---

Accepted: 11 March 2025

---

Accelerated Article Preview

---

Published online: 24 March 2025

---

Cite this article as: Großkopf, J. et al. Generalizing arene C–H alkylations by radical–radical cross-coupling. *Nature* <https://doi.org/10.1038/s41586-025-08887-2> (2025)

---

Johannes Großkopf, Chawanansaya Gopatta, Robert T. Martin, Alexander Haseloer & David W. C. MacMillan

---

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

# Generalizing arene C–H alkylations by radical–radical cross-coupling

Johannes Großkopf<sup>1</sup>, Chawanansaya Gopatta<sup>1</sup>, Robert T. Martin<sup>1</sup>, Alexander Haseloer<sup>1</sup> & David W. C. MacMillan<sup>1\*</sup>

## Affiliations:

<sup>1</sup>Merck Center for Catalysis at Princeton University, Princeton, New Jersey 08544, United States

\*Corresponding Author; email: [dmacmill@princeton.edu](mailto:dmacmill@princeton.edu)

The efficient and modular diversification of molecular scaffolds, particularly for the synthesis of diverse molecular libraries, remains a significant challenge in drug optimization campaigns.<sup>1–3</sup> The late-stage introduction of alkyl fragments is especially desirable due to the high sp<sup>3</sup>-character and structural versatility of these motifs.<sup>4</sup> Given their prevalence in molecular frameworks, C(sp<sup>2</sup>)–H bonds serve as attractive targets for diversification, though this process often requires difficult pre-functionalization or lengthy de novo syntheses. Traditionally, direct alkylations of arenes are achieved by employing Friedel–Crafts reaction conditions using strong Brønsted or Lewis acids.<sup>5,6</sup> However, these methods suffer from poor functional group tolerance and low selectivity, limiting their broad implementation in late-stage functionalization and drug optimization campaigns. Herein, we report the application of a novel strategy for the selective coupling of differently hybridized radical species, which we term *dynamic orbital selection*. This mechanistic paradigm overcomes common limitations of Friedel–Crafts alkylations via the in situ formation of two distinct radical species, which are subsequently differentiated by a copper-based catalyst based on their respective binding properties. As a result, we demonstrate herein a general and highly modular reaction for the direct alkylation of native arene C–H bonds using abundant and benign alcohols and carboxylic acids as the alkylating agents. Ultimately, this solution overcomes the synthetic challenges associated with the introduction of complex alkyl scaffolds into highly sophisticated drug scaffolds in a late-stage fashion, thereby granting access to vast new chemical space. Based on the generality of the underlying coupling mechanism, *dynamic orbital selection* is expected to be a broadly applicable coupling platform for further challenging transformations involving two distinct radical species.

In recent decades, the pace of drug discovery has become increasingly intertwined with advances in synthetic organic chemistry.<sup>7,8</sup> Notably, the need to rapidly diversify existing lead structures for structure-activity relationship (SAR) campaigns has underscored the importance of developing efficient, modular, and expedited synthetic protocols.<sup>9</sup> This synergy between drug discovery and chemical synthesis can significantly expedite the optimization of pharmacological properties in drug molecules.

In this context, the synthetic chemist aims to develop methods that harness abundant and structurally diverse functional groups as a means to maximize reaction applicability and generality.<sup>10</sup> Aromatic compounds, particularly those containing C(sp<sup>2</sup>)–H bonds, are ubiquitous in drug molecules<sup>11</sup> and widely available from commercial sources. The ability to directly engage these native C(sp<sup>2</sup>)–H bonds in functionalization reactions—without the need for prior installation of additional functional handles—would significantly streamline diversification efforts.<sup>12</sup> Recent years have seen growing interest in reactions that enable the direct functionalization of arenes, especially those that form C(sp<sup>2</sup>)–C(sp<sup>2</sup>) and C(sp<sup>2</sup>)–heteroatom (C(sp<sup>2</sup>)–Het) bonds.<sup>13,14</sup> Despite these efforts, few methods are capable of directly forging C(sp<sup>2</sup>)–C(sp<sup>3</sup>) bonds via C(sp<sup>2</sup>)–H activation in the context of late-stage cross-couplings.<sup>15–20</sup> These methods often rely on alkyl halides, which are limited in both commercial availability and applicability, and generally offer attenuated scope. There is therefore great interest in developing a modular and general platform that achieves the selective alkylation of arene C–H bonds using abundant alkyl sources. To this end, alcohols are viewed as highly desirable synthetic building blocks due to their broad commercial availability, structural diversity, and benign nature (Fig. 1A).<sup>10</sup> Classical *Friedel–Crafts* alkylation strategies use alcohols, yet often require forcing reaction conditions that severely limit their applicability in diversely functionalized systems. Furthermore, these methods typically necessitate highly electron-rich aromatic compounds and are prone to overalkylation due to increased electron density in the aromatic system upon alkylation, further constraining their use in complex synthetic contexts.<sup>5</sup>

A robust, general catalytic platform that achieves the functionalization of a wide range of C(sp<sup>2</sup>)–H bonds with alcohol alkylating agents would enable a vast expansion of accessible chemical space for alkyl–aryl substitution

54 patterns.<sup>21</sup> Moreover, a robust direct C(sp<sup>2</sup>)-H alkylation protocol would facilitate retrosynthetic analysis of  
55 complex drug targets and, in the context of late-stage functionalization, would allow for the tailored one-step  
56 diversification of structurally sophisticated molecules, including natural products, biomolecules, and small-  
57 molecule therapeutics, circumventing the need for lengthy *de novo* syntheses (Fig. 1B).

## 58 59 **Reaction Conceptualization**

60 In recent years, the synergistic merger of transition metal catalysis and photoredox chemistry has led to the  
61 introduction of new cross-coupling methods that offer exceptional selectivity under mild reaction conditions.<sup>22</sup>  
62 Nickel-based metallaphotoredox catalysis strategies have been developed to forge C(sp<sup>2</sup>)-C(sp<sup>3</sup>) bonds; these  
63 mechanisms typically involve oxidative addition of a nickel complex into a C(sp<sup>2</sup>)-halide bond.<sup>23-25</sup> However, in  
64 the context of complex drug scaffolds, introduction of the halide group requires alteration of the starting materials  
65 or direct installation under forcing conditions, which can be unfeasible or proceed with poor chemo- and  
66 regioselectivity.

67 To address this challenge, we envisioned a synthetic platform that eliminates the need for a pre-installed functional  
68 handle by bypassing the traditional oxidative addition step. Specifically, we sought to leverage previous studies on  
69 late-stage C(sp<sup>2</sup>)-H activation that employ sulfoxides to generate open-shell aryl radicals from C(sp<sup>2</sup>)-H bonds *via*  
70 light-induced electron transfer.<sup>26-28</sup> We anticipated that this aryl radical could be induced to selectively couple with  
71 a transient alkyl radical derived *in situ* from an alcohol precursor.

72 A long-standing paradigm in radical-radical cross-coupling asserts that to achieve satisfactory selectivity and  
73 prevent undesired side reactions, one of the coupling partners must be long-lived.<sup>29</sup> Recently, our group introduced  
74 the concept of *radical sorting* as a means to achieve cross-selectivity in radical-radical couplings. Under this  
75 strategy, two differentially substituted radicals are generated in solution, and selectivity is achieved through  
76 preferential capture of the less-substituted radical by the metal catalyst, followed by homolytic substitution with  
77 the more nucleophilic, higher substituted radical.<sup>30-32</sup>

78 While the logic of *radical sorting* relies on steric differences between coupling partners, one might also consider  
79 other properties that influence the strength of radical binding to a metal center. Inspired by seminal observations  
80 on the stabilization of distinct radical species by a metal center,<sup>33</sup> we sought to pursue *dynamic orbital selection* as  
81 a means to differentiate coupling partners by exploiting the different binding properties of radical orbitals to metals.  
82 Specifically, we envisioned simultaneously generating an alkyl p-radical and an aryl sp<sup>2</sup>-radical in the presence of  
83 a Cu(I) catalyst (Fig. 1C). The dynamic equilibrium between the two free radicals and their respective metal-bound  
84 states is governed by differences in bond dissociation energies between the radical and the metal catalyst and can  
85 be used to enable cross selectivity in radical-radical couplings. We expected that the Cu(I) complex would  
86 preferentially bind to the sp<sup>2</sup>-hybridized aryl radical over the alkyl p-radical, which would remain in equilibrium  
87 between the free and metal-bound states.<sup>34</sup> For the second radical capture, an additional selection event would occur  
88 based on the unfavorable coordination of an alkyl radical to an intermediate Cu(II)-alkyl species, as well as the  
89 inherently challenging reductive elimination leading to the alkyl homocoupled product. Instead, the reversibility of  
90 alkyl radical coordination, coupled with dynamic selection by the catalyst, would enable the system to selectively  
91 funnel to the desired high-valent aryl-alkyl Cu(III) species, poised to undergo facile reductive elimination.<sup>35</sup>  
92 Execution of this new *dynamic orbital selection* logic would allow the direct alkylation of C(sp<sup>2</sup>)-H bonds using  
93 abundant feedstock precursors.

94 To maximize the scope and modularity of the reaction platform, we sought to employ both alcohols and carboxylic  
95 acids as alkylating agents. The use of these two distinct alkyl radical precursors would allow for orthogonal  
96 functionalizations of two different lynchpins. Previous work by our group has demonstrated the versatile use of  
97 benzoxazolium-based reagents, known as NHC reagents, for the activation of alcohols and the release of alkyl  
98 radicals by means of photoredox chemistry.<sup>36</sup> For alkyl-substituted carboxylic acids, we envisioned a copper-  
99 assisted direct oxidation followed by irreversible decarboxylation to generate the corresponding alkyl radical (Fig.  
100 1D).<sup>37</sup>

## 101 102 **Development of the cross-coupling platform**

103 We first sought to optimize a general alkylation protocol using alcohols as the alkyl radical source. To benchmark  
104 our method against a traditional approach for direct alkylation of aromatic compounds—*Friedel-Crafts*  
105 alkylation—we selected fluorobenzene, an electron-poor arene, and Cbz-protected 4-hydroxypiperidine as the  
106 coupling partners.

107 The arene was activated with dibenzothiophene oxide (DBTO) and triflic anhydride to generate adduct **II** in a  
108 telescoped protocol without additional column purification. Under our optimized conditions, direct addition of

109 NHC-OMe-alcohol adduct **1**, Cu(I)Cl, Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbbpy)PF<sub>6</sub>, cesium acetate (CsOAc), tetrabutylammonium  
110 chloride (TBACl), dimethyl sulfoxide (DMSO), and methyl *tert*-butyl ether (MTBE), followed by irradiation with  
111 blue light-emitting diodes (LEDs) for 2 hours, led to formation of the desired cross-coupled product in high yields.  
112 Interestingly, only copper-based catalysts, particularly Cu(I)Cl, were capable of acting as efficient *dynamic orbital*  
113 *selection* catalysts, delivering the cross-coupled product in satisfactory yields. In contrast, the nickel-based catalysts  
114 previously employed for radical sorting<sup>31,32,38,39</sup> produced only minor amounts of the desired product (see  
115 Supplementary Information for details).

116 The superior performance of the more electron-rich NHC-OMe, compared to its NHC-H analog, can be attributed  
117 to its lower reduction potential of E<sub>1/2</sub> (NHC-alcohol<sup>+</sup>/NHC-alcohol) = +0.45 V (vs. SCE) (see Supplementary  
118 Information for cyclic voltammetry measurements), which allows it to outcompete competitive quenching of the  
119 excited state photocatalyst by Cu(I). Moreover, the addition of TBACl significantly enhanced the reaction yield  
120 and suppressed undesired olefin formation caused by overoxidation of the alkyl radical by *in situ*-formed Cu(II)  
121 species. We hypothesize that TBACl modulates the ligand environment of the copper catalyst, reducing its oxidative  
122 power in its Cu(II) state, analogous to other reported copper-based systems (see Supplementary Information for a  
123 detailed discussion).<sup>40,41</sup> Notably, other ligands commonly used in copper-mediated reactions did not improve the  
124 yield compared to TBACl. Both aryl and alkyl radical species were detected by radical trapping studies, including  
125 intramolecular cyclization experiments and TEMPO adduct formation. Control experiments further support the  
126 existence of a copper-mediated *dynamic orbital selection* pathway, as exclusion of metal catalyst led to a statistical  
127 amount of cross-coupled product and predominantly resulted in formation of the protodeoxygenated byproduct and  
128 reformation of the arene by hydrogen atom transfer (HAT).

129 Density functional theory (DFT) calculations support the existence of a reaction network initiated by selective  
130 radical capture by Cu(I), leading to the formation of Cu(II)-alkyl and Cu(II)-aryl species. Due to differences in  
131 bond dissociation energies, aryl radical coordination is an irreversible process, whereas alkyl radical coordination  
132 is reversible. This results in the immediate and irreversible capture of free aryl radicals by the Cu(I) catalyst,  
133 forming a Cu(II)-aryl species. This intermediate can subsequently capture either an aryl or an alkyl radical, leading  
134 to aryl homocoupling or the desired heterocoupled product, respectively, following reductive elimination from a  
135 high-valent Cu(III) species.<sup>42</sup> The high cross-coupling selectivity arises from the low temporal concentration of free  
136 aryl radicals in solution, a result of their barrierless and irreversible capture by Cu(I). This minimizes the statistical  
137 likelihood of aryl homocoupling. Furthermore, our calculations reveal a secondary selection process at the Cu(II)  
138 stage when an Cu(II)-alkyl species is formed. Reversible capture of a second alkyl radical by the Cu(II)-alkyl  
139 intermediate is thermodynamically less favored than irreversible aryl radical capture, therefore funneling the  
140 reaction toward the thermodynamically favored Cu(III) aryl-alkyl species, which rapidly undergoes reductive  
141 elimination to form the cross-coupled product.

142 The copper catalyst thus dynamically selects the appropriate radicals based on their binding properties, thereby  
143 governing cross-selectivity by guiding the reaction towards the desired high-valent Cu(III) aryl-alkyl species.  
144 Further mechanistic details are provided in the Supplementary Information.

145

## 146 Scope Evaluation

147 With optimized conditions in hand, we next set out to explore the scope of the aromatic alkylation strategy with  
148 respect to the alcohol coupling partner (Fig. 2). A range of primary alcohols with varying electronic and steric  
149 properties were productively engaged in radical-radical cross-coupling with (hetero)arene partners, generating the  
150 corresponding products in good to high yields (46–67% yield). Notably, the reaction tolerated a variety of different  
151 substitution patterns in the β-position, including secondary (**1–3**), tertiary (**4**), and even quaternary carbon centers  
152 bearing a neopentyl substitution pattern (**5**). The latter finding is particularly noteworthy, as highly β-substituted  
153 coupling partners often pose significant challenges in traditional radical cross-coupling reactions with aryl halides  
154 in the presence of sterically sensitive nickel complexes. In contrast, the copper complex employed herein is more  
155 sterically accessible as it does not require the addition of exogenous ligands.

156 A wide variety of complex secondary alcohols bearing seven- (**6**), six- (**7** and **8**), five- (**9** and **10**), and four-  
157 membered rings (**11** and **12**) were found to be suitable alkylating agents, delivering cross-coupled products in good  
158 to excellent yields (54–77% yield). Furthermore, spirocyclic alcohols (**13** and **14**) equipped with Boc-protected  
159 amines, which are notoriously difficult to engage in traditional *Friedel-Crafts* alkylation or acylation reactions,  
160 were coupled in 54% and 62% yield, respectively. Even sterically hindered 2-adamantanol was successfully  
161 coupled, affording the corresponding cross-coupled product **15** in 81% yield. A nucleoside analogue, **16**, containing  
162 a highly labile acetal protecting group, served as a competent coupling partner in our protocol (44% yield).  
163 Moreover, naturally occurring alcohols such as (–)-menthol (**17**) and derivatives of natural alcohols such as the

164 methylester of hydroxyproline (**18**) were viable coupling partners, delivering the desired products in high yields  
165 (74% and 54%, respectively). To our delight, more complexly substituted six-membered ring systems incorporating  
166 structural motifs prevalent in drug discovery, including pyridine **19** and triazolopiperazine **20**, could be converted  
167 to the respective products in synthetically useful yields (55% and 50%, respectively).

168 As outlined in Figure 2, we found a range of benzylic and allylic alcohols to be viable substrates in the cross-  
169 coupling reaction. Linear benzylic alcohols (**21–23**), allylic alcohols such as myrtenol (**24**), and cyclic benzylic  
170 alcohols (**25**) were efficiently coupled with phenyl-based arenes or sterically encumbered pyridine to deliver the  
171 desired products in high yields (60–67% yield, see Supplementary Information for extended scope).

172 To further extend the generality of the *dynamic orbital selection* system, we questioned whether tertiary radicals  
173 could be employed *en route* to desirable, yet challenging, all-carbon quaternary centers. Particularly in the context  
174 of copper-catalyzed radical cross-couplings, only quaternary centers possessing heteroatoms or two sp<sup>2</sup>-carbon  
175 substitutions had previously been reported,<sup>42,43</sup> and radical coupling using all-carbon tertiary radicals remained  
176 elusive. Although tertiary alcohols in combination with strong *Brønsted*- and/or *Lewis*-acids have been shown to  
177 alkylate C(sp<sup>2</sup>)-H bonds through *Friedel-Crafts* alkylation, these transformations lack selectivity as well as  
178 functional group tolerance in more complex settings.<sup>44</sup>

179 We were pleased to find that, by switching from CsOAc to tetrabutylammonium benzoate (TBAOBz) and using  
180 a variant of the NHC reagent (NHC-CF<sub>3</sub>) specifically designed to activate tertiary alcohols, we obtained good to  
181 high yields of coupled products (44–68% yield) across a variety of tertiary alcohols, including cyclic (**26** and **27**),  
182 spirocyclic (**28** and **29**), and non-cyclic (**30**) substrates. To our delight, despite detectable overoxidation of the  
183 tertiary radical by Cu(II), the cross-coupled product was the main reaction outcome in all cases, showcasing the  
184 robustness of this *dynamic orbital selection* approach and the efficiency of alkyl radical capture paired with  
185 reductive elimination from the Cu(III) species.

186 In a combinatorial approach, we explored the scope of the arene coupling partner. Multiple commercially  
187 available or easily accessible arenes with various (heterocyclic) substitution patterns and electronic features were  
188 successfully coupled with differently substituted alcohols (see Supplementary Information for more examples). We  
189 were pleased to note that halide-containing arenes served as effective coupling partners (**5**, **10**, **19** and **23**);  
190 importantly, the reaction conditions preserved these valuable functional handles for use in further downstream  
191 manipulations. This result highlights the functional group tolerance of this reaction and its orthogonality to  
192 established radical cross-coupling reactions, which often suffer from deleterious dehalogenation.

193 At present, the limitations of the system include highly electron-poor (hetero)arenes that do not undergo activation  
194 by DBTO, as well as functional groups prone to deleterious side reactions under the activation conditions.  
195 Additionally, alcohols containing alkyl bromides or highly coordinating motifs, such as 1,3-diols, yield the desired  
196 products in low yields due to halogen atom transfer to the aryl radical and complexation with the copper catalyst,  
197 respectively. Additional substrate tables, along with an overview of functional group and structural motif limitations  
198 may be found in the Supplementary Information.

199

## 200 **Radical-radical cross-coupling of complex scaffolds**

201 We next aimed to apply our *dynamic orbital selection* platform to more complex alcohols, particularly those  
202 derived from naturally occurring biomolecules and scaffolds commonly found in pharmacologically active  
203 compounds (Fig. 3). We successfully intercepted various aryl radicals with a range of complex alkyl radicals,  
204 including triazine **31** (51% yield) and 1,2-diols, as exemplified by the synthesis of **32** (55% yield) from an  
205 efinaconazole-derived diol. In this example, due to the exceptional regioselectivity of the NHC reagent, only the  
206 secondary alcohol was activated, leaving the tertiary alcohol untouched and available for further functionalization.

207 Complex alcohols derived from amino acids also proved to be excellent coupling partners, as demonstrated by  
208 the hydroxyproline derivative **33** (54% yield), which offers the potential for further couplings at the Boc-protected  
209 nitrogen atoms, and oxazolidinone **34** (64% yield). Additionally, we productively harnessed biomolecules,  
210 including sugars and steroids, as alkyl radical sources, generating the galactopyranose derivative **35** (73% yield)  
211 and the androsterone derivative **36** (63% yield). Furthermore, both the antiandrogen derivative **37** and  
212 tetrahydropyran **38** were obtained in high to synthetically useful yields (48% and 63%, respectively).

213 A key advantage of this radical-radical cross-coupling approach is the use of native and ubiquitous C(sp<sup>2</sup>)-H  
214 bonds without the need for substrate pre-functionalization. To highlight the utility of this direct C(sp<sup>2</sup>)-H alkylation  
215 protocol, we subjected a variety of complex arenes to our optimized conditions. In general, the regioselectivity of  
216 DBTO activation is dictated by both steric factors and the electron density of the aromatic ring.<sup>45</sup> Particularly in  
217 (hetero)aromatic systems bearing electron-donating heteroatoms such as nitrogen or oxygen, excellent  
218 regioselectivity was observed, and the corresponding alkylated products were obtained in high yields (**39**, **41** and

219 **42**, 50–76% yield). In the context of neutral arenes, such as phenyls (**40**, 60% yield) or biaryls (**44**, 53% yield),  
220 both *ortho*- and *para*-products were observed, with a preference for the *para*-position. Importantly, despite  
221 variations in the electronic nature of the intermediate aryl radical, a wide range of substituted complex alkyl radicals  
222 could be coupled, including sugars, underscoring the modularity of this protocol. We also investigated the  
223 functionalization of complex scaffolds that do not permit the introduction of a halogen atom with established  
224 methods, as such structures would be incompatible with classical radical cross-coupling strategies. Pleasingly, both  
225 boscalid (**43**) and pyriproxyfen (**45**) were functionalized with excellent regioselectivity, affording the  
226 corresponding products in 45% and 50% yields, respectively.  
227

## 228 **Late-stage functionalization and expedited synthesis of biologically active compounds**

229 In medicinal chemistry and drug development, methods to achieve the late-stage functionalization of biologically  
230 active molecules allow for straightforward diversification and open novel chemical space for SAR campaigns (3).  
231 In this context, we aimed to apply our method to the late-stage functionalization of drug molecules and other  
232 biologically active compounds, with the goal of offering a modular and general approach to accessing new alkylated  
233 chemical space without the need for lengthy, *de novo* syntheses (Fig. 4).

234 To our delight, multiple alcohol-containing drugs, including ticagrelor (**46**), losartan (**47**), and lonazolac (**48**),  
235 underwent radical–radical cross-coupling with fluorobenzene, yielding products in good to synthetically useful  
236 yields (41–67%). In the case of losartan (**47**), the scalability of the reaction was demonstrated by the successful  
237 generation of 1.24 g of the cross-coupled product in a single reaction setup. We sought to capitalize on the  
238 demonstrated functional group tolerance of this method to overcome longstanding challenges in arylating the 3'-  
239 position of a nucleoside, a modification that can alter the therapeutic properties of the nucleoside. To this end,  
240 application of our method to the functionalization of 5-methyl-2'-deoxycytidine provided the 3'-arylated product  
241 **49** in 38% yield with a diastereomeric ratio of 1.7:1.

242 Aromatic rings, among the most frequently represented structural motifs in drug compounds, are particularly  
243 attractive targets for late-stage functionalization. Selective and mild conditions are needed to preserve complex  
244 molecular structures. We benchmarked our system on a series of structurally differentiated arene-containing drug  
245 molecules, including nateglinide (**50**), gemfibrozil (**51**), nefiracetam (**52**), ibuprofen (**53**) and flurbiprofen (**54**). In  
246 all cases, cross-coupling with a variety of alcohol partners yielded the desired products in good to high yields (45–  
247 64%) without impeding the structural integrity of the drug molecules. Delightfully, the aryl radical generated from  
248 l-phenylalanine was readily cross-coupled to generate unnatural amino acid **55** (35% yield), opening the possibility  
249 of rapidly synthesizing phenylalanine-derived libraries of unnatural amino acids bearing different substitution  
250 moieties and patterns (*ortho vs. para*).

251 Recognizing the well-documented "magic methyl effect",<sup>46</sup> whereby significant enhancements in drug efficacy  
252 can be attained through the introduction of a methyl group, we aimed to address the persistent challenge of  
253 introducing a methyl group at a late stage in drug synthesis. Pleasingly, we installed a methyl group on the type 2  
254 diabetes drug empagliflozin (**56**, 37% yield) with complete regioselectivity, using methanol as a safe and benign  
255 methyl radical source. Encouraged by these results, we turned our attention to another challenge in organic  
256 synthesis: the late-stage *tert*-butylation of complex molecules. Despite recent advances that use Minisci-type  
257 additions for *tert*-butylation of heterocyclic compounds,<sup>47,48</sup> the mild and selective introduction of a *tert*-butyl group  
258 to non-heterocyclic arenes remains underdeveloped.<sup>49</sup> Using our tertiary alcohol reaction protocol, we obtained  
259 *tert*-butylated boscalid **57** in synthetically useful 33% yield and with complete control of regioselectivity.

260 A priority of drug discovery is to access synthetic targets in a streamlined and efficient manner. However,  
261 traditional arene alkylation methods used in the synthesis of drug targets, such as the multiple sclerosis drug  
262 fingolimod, often require multiple steps, including *Friedel-Crafts* acylation followed by reduction, both of which  
263 involve forcing conditions and suffer selectivity issues. By contrast, our *dynamic orbital selection* strategy delivered  
264 fingolimod (**59**) from benzene through the *n*-octylbenzene (**58**) intermediate in a total of two steps with an average  
265 yield of 50% per step. This route notably shortens the synthetic sequence without requiring additional redox  
266 interconversions or the use of hazardous chemicals and pressurized reactors.<sup>50</sup>

267 To further benchmark the applicability of *dynamic orbital selection* in the context of drug synthesis, we set out to  
268 compare our system to an industrially applied *Friedel-Crafts* alkylation *en route* to tetralone **60**, the direct precursor  
269 of the antidepressant drug sertraline (**61**). Our protocol delivered **60** in 69% yield using commercially available  
270 starting materials, making it comparable to the industrially applied synthesis.<sup>51</sup> Subsequent reductive amination of  
271 the ketone delivered sertraline (**61**) in 88% yield.  
272

## 273 **Engaging carboxylic acids in radical-radical cross-coupling**

274 Aside from alcohols, carboxylic acids are among the most widespread functional groups in medicinal chemistry  
275 and serve as attractive functionalization lynchpins due to their commercial availability. Moreover, carboxylic acids  
276 have proven to be excellent precursors to alkyl radicals in metallaphotoredox catalysis.<sup>52</sup> Therefore, we envisioned  
277 establishing carboxylic acids as coupling partners as a means to further extend the accessible chemical space of this  
278 transformation.

279 Our group previously demonstrated that carboxylic acids can be converted to alkyl radicals *via* a  
280 metallaphotoredox pathway involving capture of the alkyl radical by a copper(II) species.<sup>37</sup> To our delight, the use  
281 of CuCN with *p*-tolyl terpyridine ligand enabled successful radical–radical cross-coupling of various carboxylic  
282 acids with different arenes *via* the proposed intermediate **III** (Fig. 5). We engaged primary (**62** and **63**) as well as  
283 tertiary (**64**) carboxylic acids in *dynamic orbital selection* with high to excellent yields (52–83% yield). Moreover,  
284 a series of biologically active drug molecules were subjected to late-stage functionalization under these conditions,  
285 including naproxen (**65**, 70% yield), flurbiprofen (**66**, 69% yield), tolmetin (**67**, 48% yield), carprofen (**68**, 42%  
286 yield) and indometacin (**69**, 53% yield).

287 Finally, we sought to showcase the potential for late-stage orthogonal functionalization *via* sequential acid–aryl  
288 and alcohol–aryl radical–radical cross-couplings. Using ibuprofen (**70**) as the model compound, we first cross-  
289 coupled the corresponding alkyl radical with fluorobenzene to generate **71** in 56% yield. Subsequent treatment with  
290 DBTO and Tf<sub>2</sub>O, followed by exposure to the alcohol *dynamic orbital selection* protocol, led exclusively to  
291 alkylation of the more electron-rich dialkylated arene (**72**, 53% yield) in preference to the fluorinated aryl ring.  
292 This outcome highlights the orthogonality of the functionalization strategy and demonstrates the potential to  
293 modularly manipulate existing drug scaffolds, thereby accessing novel chemical space and more complex  
294 structures.

295  
296

## 297 **Outlook**

298 Medicinal chemists require robust methods for the late-stage derivatization of biologically active molecules in  
299 order to expedite SAR campaigns and accelerate the drug discovery process. Suitable methods should be versatile,  
300 mild, compatible with a wide range of functionalities, and employ abundant, bench-stable reagents. In this work,  
301 we introduce a new synthetic strategy to selectively alkylate the C(sp<sup>2</sup>)-H bond through an orbital-sorting radical–  
302 radical cross-coupling mechanism. We have shown that this method is capable of efficiently functionalizing  
303 complex aryl rings with a diverse range of alkyl groups derived from ubiquitous alcohol and carboxylic acid  
304 coupling partners. We anticipate that the *dynamic orbital selection* approach described herein will find widespread  
305 adoption across the applied chemical sciences.

306

## 307 **Supplementary information**

## 308 **AUTHOR INFORMATION**

### 309 **Corresponding Author**

310 **David W. C. MacMillan** – Merck Center for Catalysis at Princeton University, Princeton, New Jersey 08544,  
311 United States; orcid.org/0000-0001-6447-0587;

312 Email: [dmacmill@princeton.edu](mailto:dmacmill@princeton.edu)

313

314

### 315 **Data availability**

316 All data supporting the findings of this study are available in the main text or in the Supplementary Information.

317

318 **Competing interests:** D. W. C. M. declares an ownership interest in the Penn PhD photoreactor, which is used to  
319 irradiate reactions in this work. The other authors declare no competing interests.

320 **Acknowledgements:** The authors thank L. Harstad, D. Morgan, and A. Pace for helpful discussions. Research  
321 reported in this work was supported in part by the National Institute for General Medical Sciences of the National  
322 Institute of Health (R35GM134897) and in part by the Office of Naval Research (N000142112138). The content is  
323 solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of  
324 Health or the Office of Naval Research. J.G. thanks the Deutsche Akademie der Naturforscher Leopoldina (LPDS  
325 2023-03) for financial support. R.T.M. thanks the National Science Foundation for financial support via the MPS-  
326 Ascend Postdoctoral Research Fellowship (Grant No. 2316541). A.H. thanks the German Research Foundation

327 (DFG) for a Walter Benjamin Postdoctoral Fellowship (HA 9945/1). The authors thank Rebecca Lambert for  
328 assistance in preparing this manuscript and B. Kennedy (Lotus Separations) for assistance with compound  
329 purification.

330

331 **Author contributions:** J.G. and D.W.C.M. conceived the work. All authors designed the experiments. J.G., C.G.  
332 and A.H. performed the experiments. R.M. performed DFT calculations. J.G. and D.W.C.M. prepared the  
333 manuscript and all authors contributed to the final version.

334

335

336

337

338

339

## REFERENCES

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

1. Castellino, N. J., Montgomery, A. P., Danon, J. J. & Kassiou, M. Late-stage Functionalization for Improving Drug-like Molecular Properties. *Chem. Rev.* **123**, 8127-8153 (2023).
2. Montgomery, A. P., Joyce, J. M., Danon, J. J. & Kassiou, M. An update on late-stage functionalization in today's drug discovery. *Expert Opinion on Drug Discovery* **18**, 597-613 (2023).
3. Jana, R., Begam, H. M. & Dinda, E. The emergence of the C–H functionalization strategy in medicinal chemistry and drug discovery. *Chem. Commun.* **57**, 10842-10866 (2021).
4. Lovering, F., Bikker, J. & Humblet, C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. *J. Med. Chem.* **52**, 6752-6756 (2009).
5. Rueping, M. & Nachtsheim, B. J. A review of new developments in the Friedel–Crafts alkylation – From green chemistry to asymmetric catalysis. *Beilstein J. Org. Chem.* **6**, 6 (2010).
6. Heravi, M. M., Zadsirjan, V., Saedi, P. & Momeni, T. Applications of Friedel–Crafts reactions in total synthesis of natural products. *RSC Adv.* **8**, 40061-40163 (2018).
7. Blakemore, D. C. *et al.* Organic synthesis provides opportunities to transform drug discovery. *Nat. Chem.* **10**, 383-394 (2018).
8. Walters, W. P., Green, J., Weiss, J. R. & Murcko, M. A. What Do Medicinal Chemists Actually Make? A 50-Year Retrospective. *J. Med. Chem.* **54**, 6405-6416 (2011).
9. Cernak, T. *et al.* The medicinal chemist's toolbox for late stage functionalization of drug-like molecules. *Chem. Soc. Rev.* **45**, 546-576 (2016).
10. Wang, Y., Haight, I., Gupta, R. & Vasudevan, A. What is in Our Kit? An Analysis of Building Blocks Used in Medicinal Chemistry Parallel Libraries. *J. Med. Chem.* **64**, 17115-17122 (2021).
11. Shearer, J. *et al.* Rings in Clinical Trials and Drugs: Present and Future. *J. Med. Chem.* **65**, 8699-8712 (2022).
12. Guillemard, L., Kaplaneris, N., Ackermann, L. & Johansson, M. J. Late-stage C–H functionalization offers new opportunities in drug discovery. *Nat. Rev. Chem.* **5**, 522-545 (2021).
13. Davies, H. M. & Morton, D. Recent Advances in C-H Functionalization. *J. Org. Chem.* **81**, 343-350 (2016).
14. Zhang, L. & Ritter, T. A Perspective on Late-Stage Aromatic C–H Bond Functionalization. *J. Am. Chem. Soc.* **144**, 2399-2414 (2022).
15. Lansbergen, B., Granatino, P. & Ritter, T. Site-Selective C–H alkylation of Complex Arenes by a Two-Step Aryl Thianthrenation-Reductive Alkylation Sequence. *J. Am. Chem. Soc.* **143**, 7909-7914 (2021).
16. Michiyuki, T., Homölle, S. L., Pandit, N. K. & Ackermann, L. Electrocatalytic Formal C(sp<sup>2</sup>)–H Alkylations via Nickel-Catalyzed Cross-Electrophile Coupling with Versatile Arylsulfonium Salts. *Angew. Chem., Int. Ed.* **63**, e202401198 (2024).
17. Guillemard, L., Ackermann, L. & Johansson, M. J. Late-stage meta-C–H alkylation of pharmaceuticals to modulate biological properties and expedite molecular optimisation in a single step. *Nat. Commun.* **15**, 3349 (2024).
18. Friis, S. D., Johansson, M. J. & Ackermann, L. Cobalt-catalysed C–H methylation for late-stage drug diversification. *Nat. Chem.* **12**, 511-519, (2020).
19. Wu, J. *et al.* Remote C–H Glycosylation by Ruthenium(II) Catalysis: Modular Assembly of meta-C-Aryl Glycosides *Angew. Chem. Int. Ed.* **61**, e202208620 (2022).
20. Lerchen, A. *et al.* Non-Directed Cross-Dehydrogenative (Hetero)arylation of Allylic C(sp<sup>3</sup>)–H bonds enabled by C–H Activation. *Angew. Chem. Int. Ed.* **57**, 15248-15252 (2018).
21. Reymond, J.-L. The Chemical Space Project. *Acc. Chem. Res.* **48**, 722-730 (2015).

- 382 22. Chan, A. Y. *et al.* Metallaphotoredox: The Merger of Photoredox and Transition Metal Catalysis. *Chem. Rev.*  
383 **122**, 1485-1542 (2022).
- 384 23. Zuo, Z. *et al.* Merging photoredox with nickel catalysis: Coupling of  $\alpha$ -carboxyl  $sp^3$ -carbons with aryl  
385 halides. *Science* **345**, 437-440 (2014).
- 386 24. Sakai, H. A., Liu, W., Le, C. C. & MacMillan, D. W. C. Cross-Electrophile Coupling of Unactivated Alkyl  
387 Chlorides. *J. Am. Chem. Soc.* **142**, 11691-11697 (2020).
- 388 25. Prieto Kullmer, C. N. *et al.* Accelerating reaction generality and mechanistic insight through additive  
389 mapping. *Science* **376**, 532-539 (2022).
- 390 26. Li, J. *et al.* Photoredox catalysis with aryl sulfonium salts enables site-selective late-stage fluorination. *Nat.*  
391 *Chem.* **12**, 56-62 (2020).
- 392 27. Aukland, M. H. *et al.* Metal-free photoredox-catalysed formal C–H/C–H coupling of arenes enabled by  
393 interrupted Pummerer activation. *Nat. Catal.* **3**, 163-169 (2020).
- 394 28. Dewanji, A. *et al.* A general arene C–H functionalization strategy via electron donor–acceptor complex  
395 photoactivation. *Nat. Chem.* **15**, 43-52 (2023).
- 396 29. Leifert, D. & Studer, A. The Persistent Radical Effect in Organic Synthesis. *Angew. Chem., Int. Ed.* **59**, 74-  
397 108 (2020).
- 398 30. Liu, W. *et al.* A biomimetic  $S_{H2}$  cross-coupling mechanism for quaternary  $sp^3$ -carbon formation. *Science*  
399 **374**, 1258-1263 (2021).
- 400 31. Wang, J. Z., Lyon, W. L. & MacMillan, D. W. C. Alkene dialkylation by triple radical sorting. *Nature* **628**,  
401 104-109 (2024).
- 402 32. Chen, R. *et al.* Alcohol-alcohol cross-coupling enabled by  $S_{H2}$  radical sorting. *Science* **383**, 1350-1357  
403 (2024).
- 404 33. Qi, X., Zhu, L., Bai, R., Lan, Y. Stabilization of Two Radicals with One Metal: A Stepwise Coupling Model  
405 for Copper-Catalyzed Radical–Radical Cross-Coupling. *Sci. Rep.* **7**, 43579 (2017).
- 406 34. Ribelli, T. G., Matyjaszewski, K. & Poli, R. The interaction of carbon-centered radicals with copper(I) and  
407 copper(II) complexes. *J. Coord. Chem.* **71**, 1641-1668 (2018).
- 408 35. Casitas, A. & Ribas, X. The role of organometallic copper(III) complexes in homogeneous catalysis. *Chem.*  
409 *Sci.* **4**, 2301-2318 (2013).
- 410 36. Dong, Z. & MacMillan, D. W. C. Metallaphotoredox-enabled deoxygenative arylation of alcohols. *Nature*  
411 **598**, 451-456 (2021).
- 412 37. Kautzky, J. A., Wang, T., Evans, R. W. & MacMillan, D. W. C. Decarboxylative Trifluoromethylation of  
413 Aliphatic Carboxylic Acids. *J. Am. Chem. Soc.* **140**, 6522-6526 (2018).
- 414 38. Sakai, H. A. & MacMillan, D. W. C. Nontraditional Fragment Couplings of Alcohols and Carboxylic Acids:  
415 C( $sp^3$ )–C( $sp^3$ ) Cross-Coupling via Radical Sorting. *J. Am. Chem. Soc.* **144**, 6185-6192 (2022).
- 416 39. Tsybmal, A. V., Bizzini, L. D. & MacMillan, D. W. C. Nickel Catalysis via  $S_{H2}$  Homolytic Substitution:  
417 The Double Decarboxylative Cross-Coupling of Aliphatic Acids. *J. Am. Chem. Soc.* **144**, 21278-21286  
418 (2022).
- 419 40. Sarver, P. J. *et al.* The merger of decatungstate and copper catalysis to enable aliphatic C( $sp^3$ )–H  
420 trifluoromethylation. *Nat. Chem.* **12**, 459-467 (2020).
- 421 41. Intermaggio, N. E., Millet, A., Davis, D. L. & MacMillan, D. W. C. Deoxytrifluoromethylation of Alcohols.  
422 *J. Am. Chem. Soc.* **144**, 11961-11968 (2022).
- 423 42. Choi, S. *et al.* Copper-Catalyzed C–C Cross-Couplings of Tertiary Alkyl Halides with Anilines Enabled by  
424 Cyclopropanimine-Based Ligands. *J. Am. Chem. Soc.* **145**, 24897-24905 (2023).
- 425 43. Dow, N. W., Cabré, A. & MacMillan, D. W. C. A general N-alkylation platform via copper  
426 metallaphotoredox and silyl radical activation of alkyl halides. *Chem* **7**, 1827-1842 (2021).
- 427 44. For a recent example of Lewis and Brønsted acid mediated Friedel–Crafts alkylation with tertiary alcohols,  
428 see: Masuda, K. *et al.* Development of highly efficient Friedel–Crafts alkylations with alcohols using  
429 heterogeneous catalysts under continuous-flow conditions. *RSC Adv.* **11**, 24424-24428 (2021).
- 430 45. Kafuta, K. *et al.* Synthesis, Structure, and Reactivity of 5-(Aryl)dibenzothiophenium Triflates. *Angew.*  
431 *Chem., Int. Ed.* **59**, 1950-1955 (2020).
- 432 46. Schönherr, H. & Cernak, T. Profound Methyl Effects in Drug Discovery and a Call for New C–H  
433 Methylation Reactions. *Angew. Chem., Int. Ed.* **52**, 12256-12267 (2013).
- 434 47. Pitre, S. P., Muuronen, M., Fishman, D. A. & Overman, L. E. Tertiary Alcohols as Radical Precursors for the  
435 Introduction of Tertiary Substituents into Heteroarenes. *ACS Catal.* **9**, 3413-3418 (2019).

- 436 48. Josephitis, C. M., Nguyen, H. M. H. & McNally, A. Late-Stage C–H Functionalization of Azines. *Chem.*  
437 *Rev.* **123**, 7655-7691(2023).
- 438 49. Only limited examples of *tert*-butylations in a complex setting are reported including this method which  
439 enables the introduction of a *tert*-butyl group in estrone: Pan, A. *et al.* Synergistic Brønsted/Lewis acid  
440 catalyzed aromatic alkylation with unactivated tertiary alcohols or di-*tert*-butylperoxide to synthesize  
441 quaternary carbon centers. *Chem. Sci.* **13**, 3539-3548 (2022).
- 442 50. Balaev, A. N., Busel, A. A. & Fedorov, V. E. Kilogram-Scale Pilot Synthesis of Fingolimod. *Pharm. Chem.*  
443 *J.* **51**, 476-479 (2017).
- 444 51. Vukics, K., Fodor, T., Fischer, J., Fellegvári, I. & Lévai, S. Improved Industrial Synthesis of Antidepressant  
445 Sertraline. *Org. Process Res. Dev.* **6**, 82-85 (2002).
- 446 52. Beil, S. B., Chen, T. Q., Intermaggio, N. E. & MacMillan, D. W. C. Carboxylic Acids as Adaptive Functional  
447 Groups in Metallaphotoredox Catalysis. *Acc. Chem. Res.* **55**, 3481-3494 (2022).
- 448  
449

**Fig 1 | Conceptualization of dynamic orbital selection.** (A) Relative commercial abundance of common aryl and alkyl cross-coupling partners (heteroarenes not included; data retrieved from the Reaxys database as of November 2024). (B) Intuitive retrosynthetic disconnections enabling straight-forward syntheses of complex drug molecules. (C) Differences in binding properties of radical orbital enabling dynamic orbital selection. (D) General radical-radical cross-coupling of C(sp<sup>2</sup>)-H bonds with abundant alkyl radical precursors (this work). Ar: aryl; Cbz, benzyl oxycarbonyl; DBT: dibenzothiophene 5-oxide; Me, methyl.

450  
451  
452

**Fig 2 | Scope of the radical-radical cross coupling of arenes with alcohols.** All yields are isolated and reactions were performed on a 0.5 mmol scale with alcohol (1.0 equiv.), NHC-OMe (Ar = *p*-OMe-Ph, 1.3 equiv.), pyridine (1.5 equiv.), *t*-BuOMe (0.1 M), arene (1.5 equiv.), DBTO (1.65 equiv.), Tf<sub>2</sub>O (1.8 equiv.), CH<sub>2</sub>Cl<sub>2</sub> (0.1 M), Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbbpy)PF<sub>6</sub> (2.5 mol%), CuCl (30 mol%), CsOAc (3.0 equiv.), TBACl (3.5 equiv.), and DMSO [0.025 M (additional *t*-BuOMe ) to 0.05 M] using an integrated photoreactor (450 nm, 50% light intensity) for 2 hours at room temperature. †With NHC-H (Ar = Ph, 1.2 to 1.3 equiv.), pyridine (1.2 to 1.5 equiv.), see Supplementary Information for full detailed experimental conditions. \*With NHC-CF<sub>3</sub> (Ar = *p*-CF<sub>3</sub>-Ph, 1.5 equiv.), pyridine (1.5 equiv.), TBAOBz (3.0 equiv.), CuCl (15 mol%), see Supplementary Information for detailed experimental conditions. ‡Preformed DBT-arene adduct and Ir(ppy)<sub>2</sub>(dtbbpy)PF<sub>6</sub> (2.5 mol%) was used. §Alcohol starting material was a 1:1 mixture of diastereomers. Boc, *tert*-butyloxycarbonyl; Cbz, benzyl oxycarbonyl; d.r., diastereomeric ratio; Me, methyl; Ph, phenyl; Ts, 4-toluenesulfonyl; r.r., regioisomeric ratio; *t*-Bu, *tert*-butyl.

461  
462  
463  
464  
465  
466


**Fig 3 | Engagement of complex alcohols and (hetero)aromatic compounds in radical-radical cross coupling.** All yields are isolated and reactions were performed on a 0.5 mmol scale, see supplementary materials for detailed experimental conditions. †TFA/TFAA in combination with DBTO was used for the arene activation. Boc, *tert*-butyloxycarbonyl; Cbz, benzyl oxycarbonyl; d.r., diastereomeric ratio; Et, ethyl; Me, methyl; Ph, phenyl; r.r., regioisomeric ratio.


467  
468  
469  
470  
471  
472

**Fig 4 | Late-stage functionalization and expedited synthesis of drug molecules.** All yields are isolated, see supplementary materials for full detailed experimental conditions. \*Performed on a 2.5 mmol scale. †Performed on a 1.5 mmol scale. ‡Use of preformed DBT-arene adduct. Ac: acetyl; Bz, benzoyl; Cbz, benzyl oxycarbonyl; DMT: dimethoxytrityl; d.r., diastereomeric ratio; *i*-Pr, isopropyl; Me, methyl; *n*-Bu, normal butyl; *n*-Pr, normal propyl; Ph, phenyl; r.r., regioisomeric ratio; Trt: trityl.


473  
474  
475  
476  
477  
478  
479  
480

**Fig 5 | Scope of the radical-radical cross coupling of arenes with carboxylic acid and orthogonal functionalization.** All yields are isolated and reactions were performed on a 0.5 mmol scale with arene (1.0 equiv), DBTO (1.1 equiv.), Tf<sub>2</sub>O (1.2 equiv.), CH<sub>2</sub>Cl<sub>2</sub> (0.1 M), carboxylic acid (1.2 equiv.), Ir[dF(CF<sub>3</sub>)ppy]<sub>2</sub>(dtbbpy)PF<sub>6</sub> (2.5 mol%), CuCN (20 mol%), *p*-TolTerpy (30 mol%), BTMG (3 equiv), and DMSO [0.065 M] using an integrated photoreactor (450 nm, 100% light intensity) for 12 hours at room temperature. ‡Performed on a 2 mmol scale. BTMG, 2-*tert*-butyl-1,1,3,3-tetramethyl-guanidine; Boc, *tert*-butyloxycarbonyl; Me, methyl; *p*-TolTerpy, 4-(*p*-tolyl)-2,6-bis(2-pyridyl)pyridine; r.r., regioisomeric ratio; Tol: *para*-tolyl.






primary alcohols




secondary alcohols




from (-)-menthol

from hydroxyproline


benzylic / allylic alcohols




tertiary alcohols




complex alkyl coupling partner




complex arene scaffolds




late-stage functionalization of biologically active compounds




minor regioisomer




late-stage methylation





late-stage tert-butylation




expedited synthesis of pharmacologically relevant molecules





orthogonal functionalization



ACCELERATED ARTICLE PREVIEW